{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-22-000054","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.769355+00:00","generated_at":"2026-06-26T01:02:38.869539+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Axogen Q1 rev flat at $31M, net loss widens to $0.20/sh; Avance Phase 3 hits endpoint","bullets":["Net revenue $31.0M flat YoY; adjusted net loss $8.5M ($0.20/sh) vs $3.1M ($0.08) prior year.","Cash and investments $73.7M at Mar 31, down from $90.3M at Dec 31, 2021.","Phase 3 RECON study of Avance Nerve Graft met primary endpoint for sensory function; BLA submission planned H2 2023.","Avance showed statistical superiority over conduits for gaps >12mm (p=0.021) and faster recovery (p=0.037).","2022 revenue guidance reaffirmed $135-142M; gross margin above 80%."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-22-000054","json":"https://secwatch.observer/filing/0000805928-22-000054.json","markdown":"https://secwatch.observer/filing/0000805928-22-000054.md","text":"https://secwatch.observer/filing/0000805928-22-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000054/0000805928-22-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592822000054/axgn-20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:02:38.869539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}